Strategic partnerships Leverage Servier’s active collaboration approach reflected in recent partnerships with n-Lorem, Cytospire Therapeutics, World Heart Federation, and BioMed X to position joint venture, co-development, or sponsored research opportunities that expand into rare genetic neurological diseases, AI-driven antibody engineering, and cardiovascular/metabolic care.

Acquisition & expansion Capitalize on Servier’s strategic acquisitions and asset purchases such as the Edgewise Therapeutics muscular dystrophy assets and ongoing investments in innovative therapies to pitch expanded licensing, distribution rights, or new product collaborations in niche indications with high unmet need.

Clinical research depth Engage with Servier’s Seedpods Day and SHINEDocs community to offer research services, CRO partnerships, data analytics, and investigator-initiated trial support that align with their R&D focus and early to mid-stage science programs.

Digital & AI enablement Present AI-first tooling and data infrastructure solutions (QlikView, Apache Airflow, NoSQL, AI-focused partnerships) that support Servier’s R&D data integration, study design, and AI-driven antibody engineering initiatives at their Paris-Saclay campus.

Global outreach & inclusion Support Servier’s social-impact and workforce initiatives, including Women in Tech collaboration and broad STEM engagement, by offering training platforms, diversity-focused programs, and scalable sponsorships that boost employer branding and talent pipeline in France and beyond.